Skip to main content

Nitric oxide synthase gene expression in patients with Non-alcoholic Fatty Liver evidence

Friday, November 08, 2013 — Poster Session III

10:00 a.m. – 12:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • S Abey
  • A Del Valle-Pinero
  • A Martino
  • W Henderson


Nonalcoholic fatty liver disease has a global prevalence of 6.3 – 46%. To investigate the potential involvement of Nitric Oxide (NO) in fatty liver pathogenesis, we examined NO-related gene expression in patients with and without fatty liver. Fatty liver patients (n=8) were compared to control patients (n=8) for expression of genes within NO signaling and inflammatory pathways. Patients (50% male, Caucasians) had a mean age of 30.6 ± 7.3 years. Besides clinical data, fasting peripheral blood was collected from the patients and mRNAs was extracted (PaxGene, Qiagen). Expressions of genes within the inflammatory and NO signaling pathways were examined using RT2 ProfilerTM PCR Array (SA Biosciences) and analyzed using SA Biosciences PCR Data Analysis software. Both inflammatory and NO-signaling gene array analyses showed 2-fold downregulated NOS2 gene expression in fatty liver patients compared to control group. Fatty liver patients had significantly higher triglycerides (p = 0.005), LDL (p = 0.035), CRP (p = 0.028), BMI (p = 0.014), % body fat (p = 0.024), and significantly lower HDL (p = 0.001) compared to control. Our finding of downregulated NOS2 gene expression in fatty liver provides evidence for this gene’s involvement in fatty liver pathogenesis.

back to top